SC 13G: Statement of acquisition of beneficial ownership by individuals-Millennium Management LLC(5.2%),Millennium Group Management LLC(5.2%), etc.
10-Q: Q2 2024 Earnings Report
8-K: Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
8-K: Current report
SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Parag Saxena(18.5%),Vedanta Partners, LLC(15.9%), etc.
424B5: Prospectus
8-K: Current report
S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
8-K: Current report
10-Q: Q1 2024 Earnings Report
8-K: Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals | 8-K: Current report
Reviva Pharmaceuticals | 10-K: FY2023 Annual Report
Reviva Pharmaceuticals | 8-K: Current report
Reviva Pharmaceuticals | 8-K: Current report
Reviva Pharmaceuticals | NT 10-K: Others
Reviva Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Laxminarayan Bhat(10.2%)
Reviva Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(9.99%),TANG CAPITAL MANAGEMENT, LLC(9.99%), etc.
Reviva Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(6.32%),Steven Boyd(6.32%)
Reviva Pharmaceuticals | EFFECT: Others
No Data